People with Osteoporosis: See if Walk-BEST Gait Program Helps You Walk Safer
Official title: People With Osteoporosis Can Walk-BEST to Reduce Fall and Fracture Risk
Run by McGill University Health Centre/Research Institute of the McGill University Health Centre · NCT07621679 · Data updated 2026-11-12
This pilot study tests whether older adults with osteoporosis can use the Walk-BEST gait training with a wearable sensor to walk more safely and reduce fall risk.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 70 Years and up |
| Sex | All |
| Enrollment | 28 (estimated) |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre Academic / other |
| Drugs / interventions | denosumab, romozosumab |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | May 7, 2026 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | June 2, 2026 |
| Trial ID | NCT07621679 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 70+ with osteoporosis or fracture history who can walk independently (with or without a aid) and are willing to use a wearable sensor.
✕Probably not a fit
Participants who are unable to walk unsupervised or who cannot consent or communicate in English or French may be unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study tests the feasibility and acceptability of a technology-assisted gait training program (Walk-BEST) in adults aged 70 and older with osteoporosis. Participants are randomized 1:1 to receive the Walk-BEST program immediately or after a 3-month wait, along with a companion workbook and remote coaching during the first month. The program uses the Heel2Toe sensor and remote support to guide strength, flexibility, balance, and walking technique, followed by home practice. The trial will assess engagement, adherence, safety, and preliminary effects on walking patterns and fall risk indicators.
Why it matters
Potential benefit: If successful, the program could help older adults with osteoporosis walk more confidently and potentially reduce falls and fractures.
How similar studies have gone: Previous work in Parkinson’s and MS suggests Walk-BEST can improve gait safely; this study tests feasibility in osteoporosis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * men and women 70 years and older * able to walk independently with or without a walking aid * experienced a prior fracture after the age of 40, OR two falls in the past 12 months, OR who have a bone mineral density test (done as part of routine clinical evaluation) with a T-score \< -2.5, OR on a Health Canada-approved anti-osteoporosis medication (oral or intravenous bisphosphonate, denosumab, teriparatide, or romozosumab) to reduce fracture risk or on a bisphosphonate drug holiday (planned treatment interruption) Exclusion Criteria: * fracture sustained in the past 12 months * unable to walk unsupervised because of active medical or neurocognitive reasons * unable to provide informed consent, or cannot communicate in English or French
Where it's running
-
Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Suzanne Morin, MD — Ri-Muhc
- Study coordinator: Velizara Garkova, MSc
- Email: velizara.garkova@rimuhc.ca
- Phone: 514-934-1934
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Role of LH and hCG in adults being evaluated for endocrine disorders
This study looks at whether levels of luteinizing hormone (LH) and hCG in adults undergoing endocrine evaluation relate to their disease presence and outcomes.
-
Can a blood marker called lumican reveal hidden fragility in postmenopausal osteoporosis
This study tests whether serum lumican levels can help identify hidden fragility risk in postmenopausal women beyond what bone density shows.
-
Functional Muscle-Bone Incongruity Index: A look at muscle strength and bone health in adults
This observational study tests a composite FKUI score using handgrip strength and hip/spine bone density to see if it better reflects musculoskeletal health than each measure alone in adults undergoing routine DXA.
-
Vessel-X Bone Filling Container System for Vertebral Augmentation
A new minimally invasive vertebral augmentation approach tests the Vessel-X device to see if it safely improves pain and function in people with osteoporotic vertebral compression fractures.
-
Proximal Humerus Cortical Thickness in Post-Stroke Paresis
This study tests whether measurements of the outer bone thickness of the upper arm (the humerus) on the paretic side after a stroke reflect regional bone loss and how well they agree with standard bone density tests.
-
AI-guided diagnosis for high-risk osteoporosis populations
This pragmatic trial tests whether an artificial intelligence tool called VeriOsteo OP can help identify high-risk people for osteoporosis and guide clinical decisions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.